Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 13;107(28):12629-33.
doi: 10.1073/pnas.1007983107. Epub 2010 Jun 28.

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

Affiliations

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

Tom Walsh et al. Proc Natl Acad Sci U S A. .

Abstract

Inherited loss-of-function mutations in the tumor suppressor genes BRCA1, BRCA2, and multiple other genes predispose to high risks of breast and/or ovarian cancer. Cancer-associated inherited mutations in these genes are collectively quite common, but individually rare or even private. Genetic testing for BRCA1 and BRCA2 mutations has become an integral part of clinical practice, but testing is generally limited to these two genes and to women with severe family histories of breast or ovarian cancer. To determine whether massively parallel, "next-generation" sequencing would enable accurate, thorough, and cost-effective identification of inherited mutations for breast and ovarian cancer, we developed a genomic assay to capture, sequence, and detect all mutations in 21 genes, including BRCA1 and BRCA2, with inherited mutations that predispose to breast or ovarian cancer. Constitutional genomic DNA from subjects with known inherited mutations, ranging in size from 1 to >100,000 bp, was hybridized to custom oligonucleotides and then sequenced using a genome analyzer. Analysis was carried out blind to the mutation in each sample. Average coverage was >1200 reads per base pair. After filtering sequences for quality and number of reads, all single-nucleotide substitutions, small insertion and deletion mutations, and large genomic duplications and deletions were detected. There were zero false-positive calls of nonsense mutations, frameshift mutations, or genomic rearrangements for any gene in any of the test samples. This approach enables widespread genetic testing and personalized risk assessment for breast and ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Screening for mutations in breast and ovarian cancer genes using targeted DNA capture and next-generation sequencing.
Fig. 2.
Fig. 2.
Large genomic deletions and duplications in BRCA1 and BRCA2 identified by analysis of the read depth of sequencing data. Normalized numbers of sequencing reads are indicated for each gene. Exons are indicated by black vertical lines and intervening introns by horizontal lines. Numbers of reads for each base pair are represented in gray. Numbers of reads for each sample deviating from the median of all samples for that base pair occur at deletions (red) and at duplications (blue). DNA repetitive elements are indicated by black vertical bars (bottom of A and B). (A) The BRCA1 locus in DNA from families 153, 163, 499, and 1061. (B) The BRCA2 locus in DNA from families 578 and 591.

References

    1. King MC, Marks JH, Mandell JB New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646. - PubMed
    1. Seal S, et al. Breast Cancer Susceptibility Collaboration (UK) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239–1241. - PubMed
    1. Rahman N, et al. Breast Cancer Susceptibility Collaboration (UK) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165–167. - PMC - PubMed
    1. Gonzalez KD, et al. Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–1256. - PubMed
    1. FitzGerald MG, et al. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998;17:727–731. - PubMed

Publication types